Bruton tyrosine kinase (BTK) is encoded by the gene mapped to human chromosome Xq22. The encoded protein belongs to the Tec family of kinases.
Immunogen
The antiserum was produced against synthesized peptide derived from human BTK around the phosphorylation site of Tyr551.
Immunogen Range: 516-565
Biochem/physiol Actions
Bruton tyrosine kinase (BTK) is a key element of B-cell–receptor signaling, which facilitates interactions with the tumor microenvironment and stimulates the survival and proliferation of chronic lymphocytic leukemia (CLL) cells. The encoded protein also plays a crucial role in activation of various constitutively active pathways of CLL-cell survival, such as the Akt, extracellular signal-regulated kinase (ERK) and nuclear factor κ light-chain enhancer of activated B cells (NF-κB) pathways. Additionally, it is also necessary for chemokine-mediated homing and adhesion of B cells. Polymorphisms in the gene are associated with the development of a symptomatic primary antibody deficiency (PAD), X-linked agammaglobulinemia.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement
Cavaliere FM
PLoS ONE, 12 (2017)
Validation of the STR DXS7424 and the linkage situation on the X-chromosome.
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd JC
The New England Journal of Medicine, 369, 32-42 (2013)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.